The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical evidence from two phase 3 trials supporting statistical adjustment methods to assess confounding impact of treatment crossover on overall survival (OS).
 
Christian Kappeler
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Andrea Wagner
Employment - Bayer
 
Joachim Kalmus
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Marcia S. Brose
Honoraria - Bayer; Exelixis; Onyx
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Onyx; Oxigene
Research Funding - Bayer (Inst); Eisai (Inst); Exelixis (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Onyx
 
Martin Schlumberger
Consulting or Advisory Role - Bayer; Eisai; Genzyme; Ipsen; Sanofi
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; N-of-One
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Caris Life Sciences; Daiichi Sankyo; Eisai; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis